Skip to main
NTHI

NTHI Stock Forecast & Price Target

NTHI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeOnc Technologies Hldgs is pursuing innovative treatments for brain cancers, with a strong focus on improving drug delivery methods and candidate compounds. Despite the inherent risks of being a clinical-stage biopharmaceutical company, NeOnc has shown promise in preclinical and clinical studies and has key catalysts expected in the near future. However, the company may face financial challenges due to a potentially higher cost of bridge loans and ongoing development of their drug delivery technology.

Bears say

NeOnc Technologies Hldgs is facing fundamental risks as their drugs, while promising in tackling CNS diseases, have technical complexities in dosage determination and potential safety issues with repeated dosing. Additionally, their focus on utilizing Perillyl alcohol (POH) to cross the blood-brain barrier (BBB) may not be as effective in all CNS tumors, potentially limiting the success of their lead products NEO100 and NEO212. Furthermore, there are still uncertainties surrounding the effectiveness and safety of their drugs in clinical trials, and the limited eligibility and high relapse rates of patients for the current standard of care treatment may also pose challenges.

NTHI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neonc Technologies Holdings Inc (NTHI) Forecast

Analysts have given NTHI a Strong Buy based on their latest research and market trends.

According to 3 analysts, NTHI has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neonc Technologies Holdings Inc (NTHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.